Literature DB >> 3732329

Heterogeneity of osteogenesis imperfecta. Biochemical and morphological findings in a case of type III according to Sillence.

H Stöss, B F Pontz, H J Pesch, R Ott.   

Abstract

A male infant with pale-blue sclerae, who died at the age of 6 weeks through the aspiration of food, presented multiple fractures and deformation of the long tubular bones. The clinical and radiological findings and the course indicated osteogenesis imperfecta, type III, according to Sillence's classification. The family history was unremarkable. Light and electron microscopic studies of iliac crest bone obtained postmortem, showed an abrupt interruption of endochondral ossification, with an active periosteal ossification. In the region of the fractures, a mixed desmochondral callus was seen. The endoplasmic reticulum of the osteoblasts was markedly dilated, the mitochondria were swollen. The osteoid was reduced in quantity. A postmortem analysis of the collagen types I, II and III obtained from skin, cartilage and bone yielded chromatographically normal collagen constituents. An analysis of the amino acids of the collagen alpha-chains showed an increased hydroxylysine content. The radiological findings and the clinical course both indicated type III osteogenesis imperfecta: identical biochemical findings have been described only for type II. The morphological and biochemical findings described here may be a manifestation of a variable expressivity of type III osteogenesis imperfecta. On the other hand, heterogeneity of type II osteogenesis imperfecta cannot be ruled out.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3732329     DOI: 10.1007/bf00441849

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  17 in total

1.  [Glycosaminoglycan and collagen analyses in osteogenesis imperfecta].

Authors:  H Bleckmann; H Kresse; J Wollensak; E Buddecke
Journal:  Z Kinderheilkd       Date:  1971

2.  A study on the conversion of procollagen. Release and recovery of procollagen peptides in the culture medium.

Authors:  B F Pontz; P K Müller; W N Meigel
Journal:  J Biol Chem       Date:  1973-11-10       Impact factor: 5.157

3.  A low-viscosity epoxy resin embedding medium for electron microscopy.

Authors:  A R Spurr
Journal:  J Ultrastruct Res       Date:  1969-01

4.  Presence of type III collagen in bone from a patient with osteogenesis imperfecta.

Authors:  P K Müller; K Raisch; K Matzen; S Gay
Journal:  Eur J Pediatr       Date:  1977-04-26       Impact factor: 3.183

5.  Osteogenesis imperfecta: update and perspective.

Authors:  P H Byers; J F Bonadio; B Steinmann
Journal:  Am J Med Genet       Date:  1984-02

6.  [Lethal osteogenesis imperfecta. Definition and heterogeneity].

Authors:  P Maroteaux; L Cohen-Solal
Journal:  Ann Genet       Date:  1984

7.  Disorder of collagen metabolism in a patient with osteogenesis imperfecta (lethal type): increased degree of hydroxylation of lysine in collagen types I and III.

Authors:  E Kirsch; T Krieg; K Remberger; H Fendel; P Bruckner; P K Müller
Journal:  Eur J Clin Invest       Date:  1981-02       Impact factor: 4.686

8.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

9.  Osteogenesis imperfecta: an expanding panorama of variants.

Authors:  D Sillence
Journal:  Clin Orthop Relat Res       Date:  1981-09       Impact factor: 4.176

10.  Abnormal collagen metabolism in cultured cells in osteogenesis imperfecta.

Authors:  R P Penttinen; J R Lichtenstein; G R Martin; V A McKusick
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

View more
  1 in total

1.  Compression Fractures and Partial Phenotype Rescue With a Low Phosphorus Diet in the Chihuahua Zebrafish Osteogenesis Imperfecta Model.

Authors:  Silvia Cotti; Ann Huysseune; Daria Larionova; Wolfgang Koppe; Antonella Forlino; Paul Eckhard Witten
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-24       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.